INmune Bio: Harnessing The Power Of The Innate Immune System
Based on the theory that chronic low-grade inflammation is behind many ailments, the company’s therapies are setting out to enlist the innate immune system to combat these.
They have multiple shots at goal addressing large problems with few treatment options facing large market opportunities.
None of these are close to approval, although the company has cash for at least 18-24 months, possibly beyond that.
The recent retreat in the share price provides an opportunity, if you can tolerate the risk and have patience.